CrystalO Biopharma

Established in 2019 and based in Shenzhen, China, CrystalO Biopharma operates an innovative drug developer that specializes in the research and development of innovative ion channel drugs for mental illness and chronic kidney disease. The company's core team comes from Harvard University, Shanghai Institute of Materia Medica and other research institutes and pharmaceutical companies. The company acquired the 2020 China Science and Technology Innovation Pioneer Technology Award and Shenzhen Specialized, Refined, Featured and Original SME. In September 2025, CrystalO Biopharma closed a venture funding from new investor Fuho Capital.

CrystalO Biopharma focuses on the research and development of membrane proteins including ion channels and GPCRs for major diseases such as chronic kidney disease and mental illness. Its products include GPCRs (G protein-coupled receptors), ion channels, anti-COVID-19 protein products, soluble proteins, nanodisc-assembled membrane proteins, etc. The company has established ion channel target small molecule and protein drug technology platforms, IonFire platform and BigC platform. It has also developed high-stability antigen production platform, structure-based drug design platform, structural biology platform, multi-specific nanoantibody platform and other biotechnology platforms, and provides customers with services such as COVID-19 recombinant protein and structural analysis, drug target structure analysis, etc.

The company generates revenue by providing innovative ion channel drugs for neuropsychiatric diseases and chronic kidney disease.   The company will accelerate the advancement of its core pipeline and upgrade its technology platform.